Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Phase 4

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: Endostar
Drug: Changchun marina
Drug: cisplatin
Drug: Taxol
Drug: parapl

First Posted Date: 2015-07-31

Last Posted Date: 2015-08-04

Lead Sponsor: Nanjing NingQi Medicine Science and Technology Co., Ltd.

Target Recruit Count: 400

Registration Number: NCT02513355

Locations: 🇨🇳
Jiangsu Taizhou People's Hospital, Nanjing City, Jiangsu, China

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

Phase 4

Conditions: Advanced Lung Squamous Carcinoma

Interventions: Biological: Endostar
Drug: Docetaxel
Drug: Cisplatin

First Posted Date: 2015-07-31

Last Posted Date: 2015-07-31

Lead Sponsor: Nanjing NingQi Medicine Science and Technology Co., Ltd.

Target Recruit Count: 400

Registration Number: NCT02513342

Locations: 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
🇨🇳
The first affiliated hospital of soochow university, Soochow, Jiangsu, China

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Cisplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Procedure: Therapeutic Conventional Surgery
Drug: WEE1 Inhibitor AZD1775

First Posted Date: 2015-07-24

Last Posted Date: 2019-03-13

Lead Sponsor: University of Washington

Target Recruit Count: 12

Registration Number: NCT02508246

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

Phase 2

Completed

Conditions: Radiation Induced Oral Mucositis

Interventions: Radiation: Intensity-Modulated Radiation Therapy
Drug: Placebo
Drug: Cisplatin

First Posted Date: 2015-07-24

Last Posted Date: 2021-09-20

Lead Sponsor: Galera Therapeutics, Inc.

Target Recruit Count: 223

Registration Number: NCT02508389

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Ohio State University, James Cancer Center, Columbus, Ohio, United States
🇺🇸
Thomas-Jefferson University Hospital-Bodine Center for Cancer Treatment, Philadelphia, Pennsylvania, United States

and more 61 locations

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Phase 3

Completed

Conditions: Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Stage IVA Uterine Corpus Cancer
Stage IIIC Uterine Corpus Cancer
Stage IIIA Uterine Corpus Cancer
Stage IIIB Uterine Corpus Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2015-07-17

Last Posted Date: 2024-07-23

Lead Sponsor: Women's Cancer Care Associates, LLC

Target Recruit Count: 48

Registration Number: NCT02501954

Locations: 🇺🇸
Women's Cancer Care Associates, LLC, Albany, New York, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Atlantic Health, Morristown, New Jersey, United States

and more 4 locations

Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma

Phase 3

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Cisplatin
Drug: Fluorouracil
Radiation: Radiation therapy
Drug: Leucovorin

First Posted Date: 2015-07-17

Last Posted Date: 2015-07-17

Lead Sponsor: Taichung Veterans General Hospital

Target Recruit Count: 54

Registration Number: NCT02500940

Locations: 🇨🇳
Taichung Vaterans General Hospital, Taichung, Taiwan

Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Nivolumab
Radiation: Radiation therapy
Drug: Low dose doxorubicin
Drug: Cyclophosphamide
Drug: Cisplatin

First Posted Date: 2015-07-16

Last Posted Date: 2022-03-22

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 84

Registration Number: NCT02499367

Locations: 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Netherlands

Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung

Phase 2

Completed

Conditions: Lung Neoplasm
Adenocarcinoma

Interventions: Drug: Pemebit
Drug: Cisplatin

First Posted Date: 2015-07-15

Last Posted Date: 2021-08-06

Lead Sponsor: Chonnam National University Hospital

Target Recruit Count: 106

Registration Number: NCT02498860

Locations: 🇰🇷
Korea university Guro hospital, Seoul, Korea, Republic of
🇰🇷
Severance hospital, Seoul, Korea, Republic of
🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of

and more 4 locations

Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC

Phase 4

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Endostatin
Drug: Vinorelbine
Drug: Cisplatin

First Posted Date: 2015-07-14

Last Posted Date: 2015-07-14

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT02497118

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma
Metastatic Pancreatic Adenocarcinoma
Non-Resectable Cholangiocarcinoma
Unresectable Pancreatic Cancer
Pancreatic Adenocarcinoma
Recurrent Gallbladder Carcinoma
Recurrent Non-Small Cell Lung Carcinoma
Stage III Pancreatic Cancer
Stage IIIA Gallbladder Cancer
Stage IIIA Non-Small Cell Lung Cancer

Interventions: Drug: Gemcitabine Hydrochloride
Drug: Docetaxel
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Other: Pharmacological Study
Biological: Recombinant EphB4-HSA Fusion Protein

First Posted Date: 2015-07-13

Last Posted Date: 2023-08-14

Lead Sponsor: University of Southern California

Target Recruit Count: 61

Registration Number: NCT02495896

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy